Julia Schneider

Ms. Julia Schneider

Institute of Virology, Charité – Universitätsmedizin Berlin
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2020 in Eurosurveillance
Verified
Journal Article
Open access
VCVictor M Corman
Victor M Corman
OLOlfert Landt
Olfert Landt
MKMarco Kaiser
Marco Kaiser
RMRichard Molenkamp
Richard Molenkamp
AMAdam Meijer
Adam Meijer
CDChristian Drosten
Christian Drosten
Background: The ongoing outbreak of the recently emerged novel coronavirus (2019-nCoV) poses a challenge for public health laboratories as virus isolates are unavailable while there is growing evidence that the outbreak is more widespread than initially thought, and international spread through travellers does already occur. Aim: We aimed to develop and deploy robust diagnostic methodology for use in public health laboratory settings without having virus material available. Methods: Here we present a validated diagnostic workflow for 2019-nCoV, its design relying on close genetic relatedness of 2019-nCoV with SARS coronavirus, making use of synthetic nucleic acid technology. Results: The workflow reliably detects 2019-nCoV, and further discriminates 2019-nCoV from SARS-CoV. Through coordination between academic and public laboratories, we confirmed assay exclusivity based on 297 original clinical specimens containing a full spectrum of human respiratory viruses. Control material is made available through European Virus Archive – Global (EVAg), a European Union infrastructure project. Conclusion: The present study demonstrates the enormous response capacity achieved through coordination of academic and public laboratories in national and European research networks.

1 April 2020 in Nature
Verified
Journal Article
Closed access
PDF file
RWRoman Wölfel
Roman Wölfel
VCVictor M. Corman
Victor M. Corman
WGWolfgang Guggemos
Wolfgang Guggemos
MSMichael Seilmaier
Michael Seilmaier
SZSabine Zange
Sabine Zange
CWClemens-Martin Wendtner
Clemens-Martin Wendtner

30 November 2020 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
JMJenny Meinhardt
Jenny Meinhardt
JRJosefine Radke
Josefine Radke
CDCarsten Dittmayer
Carsten Dittmayer
JFJonas Franz
Jonas Franz
CTCarolina Thomas
Carolina Thomas
FHFrank L. Heppner
Frank L. Heppner

25 May 2021 in Science
Verified
Journal Article
Open access
PDF file
TJTerry Jones
Terry Jones
GBGuido Biele
Guido Biele
BMBarbara Mühlemann
Barbara Mühlemann
TVTalitha Veith
Talitha Veith
JSJulia Schneider
Julia Schneider
CDChristian Drosten
Christian Drosten
Correlates of infectiousness: The role that individuals with asymptomatic or mildly symptomatic severe acute respiratory syndrome coronavirus 2 have in transmission of the virus is not well understood. Jones et al. investigated viral load in patients, comparing those showing few, if any, symptoms with hospitalized cases. Approximately 400,000 individuals, mostly from Berlin, were tested from February 2020 to March 2021 and about 6% tested positive. Of the 25,381 positive subjects, about 8% showed very high viral loads. People became infectious within 2 days of infection, and in hospitalized individuals, about 4 days elapsed from the start of virus shedding to the time of peak viral load, which occurred 1 to 3 days before the onset of symptoms. Overall, viral load was highly variable, but was about 10-fold higher in persons infected with the B.1.1.7 variant. Children had slightly lower viral loads than adults, although this difference may not be clinically significant. Science , abi5273, this issue p. eabi5273

1 August 2020 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
MBMerle Margarete Böhmer
Merle Margarete Böhmer
UBUdo Buchholz
Udo Buchholz
VCVictor M Corman
Victor M Corman
MHMartin Hoch
Martin Hoch
KKKatharina Katz
Katharina Katz
AZAndreas Zapf
Andreas Zapf

8 March 2020 in medRxiv
Verified
Preprint
Open access
PDF file
RWRoman Wölfel
Roman Wölfel
VCVictor M Corman
Victor M Corman
WGWolfgang Guggemos
Wolfgang Guggemos
MSMichael Seilmaier
Michael Seilmaier
SZSabine Zange
Sabine Zange
CWClemens-Martin Wendtner
Clemens-Martin Wendtner
Coronavirus disease 2019 (COVID-19) is an acute respiratory tract infection that emerged in late 2019 1,2 . Initial outbreaks in China involved 13.8% cases with severe-, and 6.1% with critical courses 3 . This severe presentation corresponds to the usage of a virus receptor that is expressed predominantly in the lung 2,4 . By causing an early onset of severe symptoms, this same receptor tropism is thought to have determined pathogenicity but also aided the control of severe acute respiratory syndrome (SARS) in 2003 5 . However, there are reports of COVID-19 cases with mild upper respiratory tract symptoms, suggesting a potential for pre- or oligosymptomatic transmission 6-8 . There is an urgent need for information on body site - specific virus replication, immunity, and infectivity. Here we provide a detailed virological analysis of nine cases, providing proof of active virus replication in upper respiratory tract tissues. Pharyngeal virus shedding was very high during the first week of symptoms (peak at 7.11 × 10 8 RNA copies per throat swab, day 4). Infectious virus was readily isolated from throat- and lung-derived samples, but not from stool samples in spite of high virus RNA concentration. Blood and urine never yielded virus. Active replication in the throat was confirmed by viral replicative RNA intermediates in throat samples. Sequence-distinct virus populations were consistently detected in throat- and lung samples of one same patient. Shedding of viral RNA from sputum outlasted the end of symptoms. Seroconversion occurred after 6-12 days, but was not followed by a rapid decline of viral loads. COVID-19 can present as a mild upper respiratory tract illness. Active virus replication in the upper respiratory tract puts prospects of COVID-19 containment in perspective.